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HAART in terms of effectiveness and cost, in a sample of
HIV patients representative of those currently treated.
PID8
COST-EFFECTIVENESS OF CIPROFLOXACIN  
HYDROCORTISON VERSUS NEOMYCIN  
POLYMIXIN  HYDROCORTISON IN THE 
TREATMENT OF ACUTE OTITIS EXTERNA
Lafuma A1, Fagnani F1, Berdeaux G2
1Cemka SA, Bourg-la-Reine, France; 2Alcon SA, Rueil-
Malmaison, France
OBJECTIVE: The aim of this study was to compare the
cost-effectiveness of a fixed topical combination of cipro-
floxacin and hydrocortison (CH) with a fixed topical com-
bination of polymixin neomycin and hydrocortison (PNH)
in the treatment of acute otitis externa (AOE), in France.
METHODS: Two randomized controlled clinical trials
were conducted comparing the clinical failure rate of
ciprofloxacin alone with CH and PNH: one in Europe
(682 patients of whom 242 were French) and the other in
the USA (728 patients). The resource utilization and cost
of clinical failure were estimated from a French panel of
ENT specialists and GPs. A model was constructed to sim-
ulate the current management of PNH and CH in France.
Sensitivity analyses were conducted using estimates from
each study and from the pooled analysis. Two perspectives
were considered: societal and third party payer. RESULTS:
The probability to have a bacterial failure was 2.4 lower
(pooled analysis; P  0.0001) in the ciprofloxacin-treated
patients whose infection was documented with Pseudomo-
nas Aeruginosa (2/3 of species). The clinical failure rate
was 1.9 lower (pooled analysis; P  0.05) in the same pa-
tients while no difference was found on the other species.
Second line therapy included a bacteriological sample
(21%), an oral antibiotic (92%) and an anti-inflammatory
agent (50%), at a mean cost of 107€. Clinical failure rate
estimated by the model was 6.6% with CH and 9.3% with
PNH. The incremental cost of CH over PNH, due to its
better efficacy, was 5.25€ according to the third party
payer perspective and 7.20€ according to the society.
CONCLUSION: Because ciprofloxacin is more effective on
Pseudomonas Aeruginosa, the most often encountered
species in AOE, a fixed combination of ciprofloxacin and
hydrocortisone allows to reduce the clinical failure rate
and its cost, in comparison to PNH.
Mean cost per
patient-year HAART CONTROL COST P value
ART 35 695 13 156 171 0.0001
Other treatments 16 490 43 092 62 0.0560
Hospital 32 136 42 790 25 0.3736
Total 84 321 99 038 15 0.4597
PID9
PATIENTS’ COMPLIANCE AND
COST-EFFECTIVENESS OF SELECTED ORAL 
ANTIBACTERIALS IN INPATIENT TREATMENT 
OF SKIN AND SOFT TISSUE INFECTIONS
Schädlich PK1, Brecht JG1, Frank U2, Huppertz E3
1PAREXEL GmbH InForMed Outcomes Research & 
Pharmacoeconomics, Berlin, Germany; 2Institute of 
Environmental Medicine and Hospital Epidemiology, University 
Hospital Freiburg, Freiburg, Germany; 3Aventis Pharmaceuticals 
Deutschland GmbH, Bad Soden, Germany
OBJECTIVES: To investigate the impact of patient com-
pliance on cost-effectiveness of the following oral anti-
bacterials in in-patient treatment of mild to moderate su-
perficial skin and soft-tissue (SST) infections from the
perspective of hospitals in Germany: amoxicillin/clavu-
lanic acid 500/125 mg thrice daily (AMC); cefpodoxime
proxetil 200mg twice daily (CPD); cefuroxime axetil
500mg twice daily (CXM); ciprofloxacin 500mg twice
daily (CIP); or roxithromycin 300mg once daily (ROX).
METHODS: An economic model was used to quantify
the cost-effectiveness ratio (CER) cost per successfully
treated patient of each alternative, based on decision-tree
technique synthesizing published data, the results of a
hospital survey and expert knowledge. Costs were exclu-
sively those incurred by hospitals. The method of the to-
tal differential then was used to quantify the impact of
the respective compliance rate on the CER of each alter-
native based on average values of the model parameters.
RESULTS: There were 3 groups of CERs: 105 DM (ROX)
with once, between 175 and 193 DM (CXM, CPD, CIP)
with twice, and 265 DM (AMC) with thrice daily appli-
cation. The application-specific compliance rate had by
far the greatest impact on each CER. This impact was
about 1.5- to 3-fold of that of the clinical effectiveness
and about 1.9- to 4.7-fold of that of the acquisition cost
per unit of each alternative. In the sensitivity analysis, the
robustness of the model was shown in a Monte Carlo
simulation. After 10,000 computations each, the cost-
effectiveness acceptability curves of the alternatives again
showed 3 distinct groups. Once daily application (ROX)
with the highest compliance rate was most favourable
followed by twice (CXM, CPD, CIP) and thrice (AMC)
daily application with moderate and low compliance, re-
spectively. CONCLUSIONS: Choosing an alternative as-
sociated with high compliance or improving patient com-
pliance highlights an important saving potential for hospitals
in the treatment of SST infections.
PID10
COST-EFFECTIVENESS ANALYSIS OF 
ANTIBIOTIC PROPHYLAXIS IN
INTRA-ABDOMINAL SURGERY
Rozenson O, Stratchounski L
State Medical Academy, Smolensk, Russia
OBJECTIVES: To evaluate the practice and conduct eco-
nomic analysis of antibiotic prophylaxis (ABP) in intra-
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abdominal surgery in Smolensk Regional Hospital (SRH)
and to assess the impact of educational (lectures, infor-
mation bulletin) and administrative (practical recommen-
dations) activity in SRH on ABP practice. METHODS:
Analysis was based on patient data gathered retrospec-
tively between 01/01/93–01/07/93 and 01/01/98–01/07/
98. Three hundred and twenty seven patients who under-
went open cholecystectomy (OCE), appendectomy (AE)
and hernia repair (HR) were included in analysis. ABP
frequency and quality (selection of antimicrobials, dosage
regimens, route of administration, post-operative dura-
tion) were assessed. For economic evaluation ABP Thresh-
old Cost/Wound Infection Treatment Cost (ABP-TC/
WITC) ratio was estimated. ABP-TC was calculated by
multiplication Numbers Needed to Treat and ABP cost.
RESULTS: In 1993 none of the patients received ABP, in
1998 the following ABP frequency was registered: OCE-
78% (77/99), HR-46% (18/39), AE-0%. In case of OCE,
I–II and III generation cephalosporins were administrated
in 57% and 47% cases, respectively. AB dosages, routes
of administrations were appropriate in all cases. TC-
ABP/WITC ratio for OCE was 520/5355  1/10.3 (RUB,
1999). In 1993 antibacterial administration without evi-
dence of postoperative infection was registered for OCE
in 82%, AE-68%, HR-33% cases; in 1998 for OCE in
31%, AE-68%, HR-34% cases. CONCLUSION: (1) ABP
in OCE is cost-effective compared to no-ABP strategy
and leads to 10 times reduction of hospital costs; (2) Edu-
cational and administrative activities have a positive im-
pact on ABP practice; (3) Monitoring of ABP practice
and feedback to surgeons should be implemented in hos-
pitals for the optimization of ABP.
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THE PEACE PROJECT (PRESCRIPTION AND 
EFFECTIVENESS OF ANTIBIOTIC IN CLINICAL 
EXPERIENCE): RESULTS OF THE
FEASIBILITY STUDY
Degli Esposti L1, Valpiani G1, De Portu S1, Ceccarelli PL1, 
Sturani A2, Cocchi R2, Degli Esposti E3
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Hospital, Ravenna, Italy; 3Health Directorate, Ravenna Local 
Health Unit, Ravenna, Italy
OBJECTIVE: to evaluate the structure and the admission
process for acute pyelonephritis (APN) and to qualify the
different alternatives. To calculate costs associated to any
therapeutic, antibiotic or not, and diagnostic, laboratory
or instrumental pathway and to notice their behaviours.
To estimate the amount of this share of hospital costs on the
global and to compare them to reimbursement. METHODS:
A retrospective analysis was made of all admissions with
a diagnosis of APN in the Nephrology Department of
Ravenna Local Health Unit between 1/1/1985 and 31/12/
1998 as well as an assessment of therapeutic costs and di-
agnostic charges (defined clinical costs) and reimburse-
ments in accordance with the DRG. Data were collected
thanks to a specific software purposely developed. An
economic analysis was conducted relating costs to length
of stay and to risk factors. RESULTS: The number of pa-
tients admitted was determined (69 females and 8 males,
aged 35.4  16.8). Average duration of hospitalization:
11.2  3.2 days. Total clinical costs: ITL. 81,389,282,
69.3% due to tests and 30,7 to drugs (mean cost per patient:
ITL. 1,190,015 for DRG 320, ITL. 1,049,115 for DRG 321
and ITL. 832,540 for DRG 322, respectively: 22.9%,
31.7%, and 24.6% of the reimbursement). Clinical costs
peaked in first days, caused by diagnostic ones, then
tailed off gradually. The 62.7% of tests was performed
within the third day. The mean cost of this period next to
admission was the 37.9% of the total mean cost per pa-
tient. DISCUSSION: the analytical knowledge of diag-
nostic and therapeutics pathways premises to find out the
clinical algorithms and their costs and to analyze the rela-
tionship between resources and results. The clinical costs
for the APN patient in hospital account for a consider-
able share of the DRG reimbursement which may there-
fore be “overbalanced” by the hotel costs (not clinical).
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THE IMPACT OF PRICE ELASTICITY OF 
DEMAND ON CONSUMPTION—AMPICILLIN/
AMOXICILLIN MARKET SURVEY IN BULGARIA, 
1995 AND 1999
Borissov B, Popova M, Koulaksazova R
Bulgarian Drug Agency, Sofia, Bulgaria
OBJECTIVES: To investigate how price elasticity of de-
mand reflects consumers’ response to price change by
means of ATC/DDD analysis for evaluation of consump-
tion and comparative sale and price analysis, referred to
two antibiotics in oral dosage forms, ampicillin (A) and
amoxicillin (Ax). METHODS: Data were gathered from:
a) the import of wholesalers, b) the reports of local man-
ufacturers for the domestic market. RESULTS: The in-
crease of drug price under elastic demand results in de-
crease of demand (in packs), while in inelastic demand
higher price will cause increase in sales. Demand curve
may affect drug consumption presented in DDD/1000/
day as well as price per 1 g active substance. Two kinds
of ampicillin (A1 and A2) and amoxicillin (Ax1 and Ax2),
both market leaders in terms of demand, were analyzed.
In 1995, A1 and Ax1 had lower price (per pack) and dou-
ble sales than A2 and Ax2. However A1 and Ax1 had elas-
tic demand-
  2.11 for A1 and 
  2.32 for Ax1. The de-
mand for A2 and Ax2 was inelastic (
  0.29 and 
 
0.58). In ampicillines A1 increased the price, A2 decreased
the price. In 1999, they both had lower sales. Further-
more, DDD/1000/day for A1 dropped from 1.15 in 1995
to 0.56 in 1999, the price per 1 g active substance also
was reduced. In amoxicillines, both products increased
the price. Ax1, being in elastic condition in 1995, de-
creased the quantity of demand twice. Ax2, starting from
inelastic market, increased the price and in 1999 ob-
tained considerable augmentation of sales, higher DDD/
1000/day/from 1.2 to 2.58/and lower price per 1 g active
substance. CONCLUSIONS: The degree of elasticity of
